Search Tag: DOACs

2025 27 May

What is the most effective way to control bleeding in patients taking direct oral anticoagulants (DOACs)? Are reversal agents warranted in every case? These are among the key questions addressed during a lightning talk at Euroanaesthesia 2025.    As the global use of DOACs continues to rise, the need for clinicians to confidently manage asso1Read more

2024 30 Jul

  Direct oral anticoagulants (DOACs) like apixaban, edoxaban, rivaroxaban (all FXa inhibitors), and dabigatran (a thrombin inhibitor) have been used for many years, with their generic versions becoming increasingly available. Though DOACs have a lower risk of serious bleeding, such as intracranial haemorrhage, compared to vitamin K antagonists, 1Read more

2019 26 Sep

Specific treatment options for factor Xa inhibitor-related bleeding, focusing on drugs like rivaroxaban, apixaban, and edoxaban.   Non-vitamin K oral anticoagulants (NOACs/DOACs) are direct reversible inhibitors of factor Xa. These drugs are also reversible inhibitors versus warfarin or other vitamin K antagonist that are used in Europe. 1Read more